Belantamab Mafodotin Plus Cyclophosphamide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Interim Results from the UK Myeloma Research Alliance Prommise Clinical Trial
Rakesh Popat(University College London Hospitals NHS Foundation Trust), Christopher Parrish(Children's Medical Center), Frank Larkin(Moorfields Eye Hospital NHS Foundation Trust), Marzia Rahman(Peter MacCallum Cancer Centre), Thea Chandler(Leeds Teaching Hospitals NHS Trust), Gordon Cook(University of Leeds), Lydia Sarah Hui Lee(University College London), Laura Clayton(University of Leeds), Robert Cicero(University of Leeds), Ceri Bygrave(Cardiff and Vale University Health Board), Sarah Brown(University of Leeds), Charlotte Pawlyn(Royal Marsden NHS Foundation Trust), Martin Kaiser(Royal Marsden NHS Foundation Trust), Hanna Renshaw(University College London Hospitals NHS Foundation Trust), Sadie Roberts(University of Leeds), Matthew Jenner(University Hospital Southampton NHS Foundation Trust), Victoria Ware, Dean Smith(University of Nottingham), Jennifer Ryan(San Francisco VA Medical Center), Andrew Hall(University of Leeds), Simona Degli Esposti(Moorfields Eye Hospital NHS Foundation Trust), Amrutha Sridhar(University College London Hospitals NHS Foundation Trust)
Cited by 3
Related Papers
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Mesenchymal stem cells avoid allogeneic rejection
|Journal of Inflammation|2005|914
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719